Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) operates in the clinical-stage biotechnology sector, specializing in CRISPR-based gene editing therapies. The company witnessed a notable decrease in the stock market today.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.1% on Feb 3, 2026 18:28

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story

The FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy, allowing the company to resume late-stage development of nexiguran ziclumeran. This decision addresses previous safety concerns and is expected to refocus Intellia's value story, although a separate hold on the cardiomyopathy study remains. The market will now focus on the trial's progression and future regulatory updates, as Intellia's stock has seen recent gains despite longer-term declines.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-lifts-magnitude-2-hold-refocusing-intellias-attr-value-s

Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal

Baird has updated its financial model for Intellia Therapeutics, Inc. (NTLA), raising its price target to $7 and maintaining a Neutral rating after the FDA lifted a clinical hold on the Nex-z hATTR-PN trial. H.C. Wainwright also increased its price target to $25 and maintained a Buy rating, citing manageability of Nex-Z's risks and increasing the probability of approval. Intellia Therapeutics is a clinical-stage biotechnology company focused on CRISPR-based gene editing therapies.

https://finviz.com/news/295524/baird-updates-intellia-therapeutics-inc-ntlas-financial-model-following-nex-z-clinical-hold-removal

Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial

Intellia Therapeutics (NTLA) saw its shares drop 12.6% despite the FDA lifting the clinical hold on its MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis. The decision allows patient enrollment to resume with enhanced liver safety monitoring, marking a significant regulatory step for its CRISPR-based therapy. However, the MAGNITUDE cardiomyopathy trial remains on hold, and investors are weighing renewed trial progress against ongoing clinical, regulatory, and financing risks.

https://www.sahmcapital.com/news/content/why-intellia-therapeutics-ntla-is-down-126-after-fda-lifts-hold-on-key-crispr-trial-2026-01-30

Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views

Eleven analysts have provided varied ratings for Intellia Therapeutics (NASDAQ: NTLA), with an average price target of $14.18, representing a 31.6% decrease from the previous average. Despite some decreases in price targets, the company shows strong financial metrics such as 51.27% revenue growth and above-average net margin, ROE, and ROA, alongside a sound debt-to-equity ratio. Intellia Therapeutics specializes in CRISPR/Cas9-based gene-editing therapies for genetically defined diseases and has collaborations with Regeneron and Novartis.

https://www.benzinga.com/insights/analyst-ratings/26/01/50208100/breaking-down-intellia-therapeutics-11-analysts-share-their-views

Intellia Therapeutics to resume dosing of gene therapy in Phase III trial

Intellia Therapeutics has received FDA approval to resume patient enrollment and dosing in its MAGNITUDE-2 Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), after a clinical hold was lifted. The hold was initially placed following the death of a patient in a related trial, MAGNITUDE, which remains on hold. Intellia's stock price increased following the announcement, and the company has agreed to modifications including enhanced safety monitoring and increased target enrollment for MAGNITUDE-2.

https://www.clinicaltrialsarena.com/news/intellia-therapeutics-to-resume-dosing-of-gene-therapy-in-phase-iii-trial/

Trending Today

Solana ($SOL) Crypto Forecast: Down 6.0% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.9% Today

Gold ($XAU) Commodity Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Revvity ($RVTY) Stock Forecast: Down 5.3% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.1% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Down 6.1% Today

FedEx Corporation ($FDX) Stock Forecast: Up 5.5% Today

Intellia Therapeutics, Inc. Price History

20.00.2026 - NTLA Stock was up 5.0%

• Intellia Therapeutics (NTLA) witnessed a significant bullish movement recently, possibly influenced by ARK Invest's continuous buying and increased position in the company.
• Despite conflicting valuations, investor confidence in Intellia's clinical pipeline and overall market trends has supported the stock's upward trajectory.
• The company's recovery from a previous decline, ongoing progress in clinical trials, and favorable analyst recommendations have all reinforced investor confidence and contributed to the positive market movement.
• ARK's consistent investment in Intellia, despite past stock fluctuations, reflects strong confidence in the company's future prospects and the effectiveness of its CRISPR-based therapy approach.

13.00.2026 - NTLA Stock was up 9.3%

• The bullish movement in NTLA stock can be attributed to positive analyst sentiments and Buy ratings from firms like TD Cowen, UBS, and Barclays, indicating confidence in the company's future performance.
• Despite recent setbacks such as the FDA clinical hold on its lead gene editing trial due to safety concerns, investors may be optimistic about the company's ability to address these issues and move forward with its clinical trials and regulatory plans.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could also be fueling investor optimism, as it provides a platform for the company to showcase its developments and potentially attract more interest from the market.
• The conflicting views on NTLA's valuation, with some considering it undervalued while others pointing out its high Price-to-Sales ratio, highlight the complexity of assessing the stock's true worth and the importance of considering various factors before making investment decisions.

21.00.2026 - NTLA Stock was up 15.0%

• Conflicting valuation signals are evident for the stock, as with a DCF model suggesting undervaluation but a P/S ratio indicating overvaluation compared to industry peers.
• Renewed interest in the stock has been sparked by ARK Investment's increased stake and the upcoming J.P. Morgan Healthcare Conference.
• ARK Invest, led by Cathie Wood, has shown confidence in the company's future prospects by acquiring NTLA shares for three consecutive days.
• Despite positive clinical trial progress and recent gains, the stock's valuation remains a matter of debate among investors and analysts.

27.00.2026 - NTLA Stock was up 5.8%

• NTLA stock soared by 10% today in a strong bullish movement.
• A clinical hold on one of Intellia's advanced gene therapy trials for ATTRv-PN was lifted by the FDA, allowing the company to restart patient enrollment.
• The FDA's approval to resume the trial has instilled confidence in Intellia's gene editing initiatives, leading to a notable surge in the stock price.
• Investors are keenly watching for further regulatory decisions on Intellia's clinical trials, especially concerning the ATTR amyloidosis program, which is expected to impact the stock's performance in the near term.

27.00.2026 - NTLA Stock was up 8.2%

• The rise in NTLA's stock price is linked to increased institutional investment from ARK Invest and positive updates on previous clinical hold concerns.
• CEO John Leonard's statement that a patient fatality in the nex-z program was not due to liver toxicity likely reassured investors and hinted at a potential lifting of the FDA hold, bolstering investor confidence.
• The upcoming regulatory decisions on the company's clinical trials, particularly regarding its hereditary angioedema (HAE) candidate, Lonvoguran Ziclumeran, are key points of interest for investors looking at future growth potential.
• Despite uncertainties around its ATTR amyloidosis program and mixed analyst ratings, ARK Invest's recent buying activity demonstrates investor optimism and readiness to handle the volatility often seen with biotech stocks like NTLA.

22.00.2026 - NTLA Stock was up 5.8%

• NTLA saw a notable bullish trend today, potentially influenced by several key factors:
• A recent surge in the company's stock price and increased attention from ARK Investment and the J.P. Morgan Healthcare Conference have attracted investor interest.
• Varied signals on valuation, including indications of both undervaluation based on a DCF model and potential overvaluation suggested by a high P/S ratio, may have led to market volatility and trading possibilities.
• The generally optimistic outlook for the gene editing industry, underscored by anticipated market expansion and transformative prospects for genetic disease treatment, may have also bolstered NTLA's bullish movement.
• Investors weighing the risks associated with stock volatility, clinical trial results, and regulatory challenges within the gene editing market could have also contributed to NTLA's market performance.

28.00.2026 - NTLA Stock was down 8.8%

• NTLA saw a decline in its stock value as the FDA removed the clinical hold on one of its gene therapy trials for ATTRv-PN, causing uncertainty in the market.
• The ongoing hold on the trial for ATTR-CM due to severe side effects and a patient's death added to the pessimism surrounding NTLA.
• Despite the positive development of the FDA allowing the resumption of patient enrollment in one trial, concerns about regulatory issues and safety continued to impact NTLA's stock performance.
• Investors appear cautious about potential safety implications on NTLA's future trials and its ability to handle regulatory hurdles efficiently.

16.00.2026 - NTLA Stock was up 6.7%

• Continued buying activity of Intellia Therapeutics (NTLA) stock by a prominent investor totaling approximately $682,000 has boosted investor confidence and pushed the stock price up.
• Despite recent challenges such as regulatory issues and a decline in stock price, Intellia's recovery and positive clinical trial advances have led to a 32% increase in stock value year-to-date, reflecting optimism among investors.
• Initial concerns regarding brokerage ratings and insider selling have been overshadowed by a recent purchasing spree by a notable investor and the company's strong Q3 earnings performance.
• The market's positive response to the ongoing investor confidence and growth potential of Intellia Therapeutics, despite recent obstacles, indicates a bullish trend in the market.

15.00.2026 - NTLA Stock was down 5.0%

• Despite facing safety concerns leading to the halting of Intellia Therapeutics' MAGNITUDE ATTR-CM trial by the FDA, the stock saw a notable surge of 20.7%. This unexpected positive movement could be linked to various factors:
• The market may be responding favorably to the ongoing Phase 3 ionvo-z trial for hereditary angioedema, which is currently fully enrolled and expected to yield results in mid-2026, potentially driving growth.
• The increased acquisition of 92,485 NTLA shares by SG Americas Securities LLC possibly boosted investor confidence, despite recent insider selling activities.
• Analysts expressing optimism about Intellia Therapeutics, with TD Cowen assigning a Buy rating, could have also played a role in the stock's upward trajectory, standing out amidst the general market pessimism.

03.01.2026 - NTLA Stock was down 5.1%

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

30.00.2026 - NTLA Stock was down 7.6%

• The FDA's decision to lift the clinical hold on Intellia's Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) resulted in a temporary boost in the stock price.
• However, the ongoing hold on the MAGNITUDE trial for cardiomyopathy patients, attributed to severe liver-related side effects, raised uncertainties and potential concerns among investors, contributing to the recent bearish trend.
• Despite the positive development of trial resumptions, persistent safety concerns and regulatory scrutiny surrounding Intellia's gene therapy programs likely influenced investor sentiment, leading to the bearish market activity.
• The diverse analyst ratings and the decrease in the average price target may have also impacted the downward movement, reflecting differing perspectives on the company's future despite its strong financial performance.

30.00.2026 - NTLA Stock was down 6.9%

• The FDA lifted a clinical hold on one of Intellia's late-stage gene therapy trials for hereditary transthyretin amyloidosis, allowing the company to resume patient enrollment. This news initially resulted in a 10% rise in shares.
• Despite the positive development regarding the lifted clinical hold, the bearish movement may be linked to the continued hold on another trial for ATTR-CM due to severe liver-related side effects, including a patient's death.
• Intellia's financial performance remains solid, with revenue growth and strong ratios. However, market sentiment could have been affected by uncertainties related to the paused trial and the necessity for new risk mitigation measures.
• Analysts have provided diverse ratings for Intellia Therapeutics, with some lowering price targets. This may be indicative of concerns about the regulatory obstacles facing the company, despite the promising nature of its gene-editing therapies.